Table 3 Longitudinal outcomes of baseline round (R1) referred women who were also screened at the MARZY follow-up round (R2)
Outcome | Non-attendee at R1 (n = 33) | Attendee at R1 (n = 109) |
|---|---|---|
Between MARZY study rounds | Â | Â |
Screening result | Â | Â |
 Positive | 2 (7.69%) | 19 (21.35%) |
 Negative (attended routine screening) | 24 (92.31%) | 66 (74.16%) |
 Did not undergo any screening since R1 | 0 (0.00%) | 4 (4.49%) |
 Missing | 7 | 20 |
 Total | 33 | 109 |
At MARZY study R2 | Â | Â |
Screening test result | Â | Â |
 ASC-US+ only | 0 (0.00%) | 3 (2.75%) |
 hrHPV+ only | 4 (12.12%) | 8 (7.34%) |
 Both positive | 2 (6.06%) | 4 (3.67%) |
 Negative | 27 (81.82%) | 94 (86.24%) |
 Total | 33 | 109 |
Colposcopy referred and attendance status | Â | Â |
 No attendance | 5 (83.33%) | 6 (40.00%) |
 Attended | 1 (16.67%) | 9 (60.00%) |
 Not applicable (screen-negative) | 27 | 94 |
 Total | 33 | 109 |